Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
皓天策略投资顾问(深圳)有限公司
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
2023-02-03 22:00
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer
2023-01-10 21:00
CPIC Life (HK) Launches the "CPIC Elite Club" to Build Core Competitiveness of "CPIC Services"
2023-01-03 17:03
CPIC: "CPIC Elite Club" Creates High Quality Services Escorts for Healthy Living
2022-12-21 15:26
CPIC Life (HK) Launches "CPIC Elite Club" Offering Variety of Benefits to Customers
2022-12-19 20:00
Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
2022-12-13 22:30
Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
2022-12-09 22:30
Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs
2022-11-21 22:00
Treadwell Therapeutics Announces A Presentation at the 2022 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
2022-11-11 22:09
CPIC Achieved a Revenue of RMB255.1 Billion In 20221H, Improving its Margin and Adhering To the Long-Term Value
2022-08-31 15:26
CPIC's Insurance Business Revenue Growth in 1H 2022 hit a New High in The Past Three Years
2022-08-29 08:42
CMGE ANNOUNCES 2022 INTERIM RESULTS
2022-08-26 16:17
CPIC: Hand in hand to create prosperous business, rooting in Hong Kong to gallop forward courageously
2022-07-06 15:35
CPIC celebrates 25th anniversary of Hong Kong's return to China, prospering together with GBA
2022-07-05 14:03
Arrail Group Announces FY2022 Annual Results
2022-06-28 15:10
HUANENG POWER INTERNATIONAL, INC. Announcement of Intention to Delist American Depositary Shares from the New York Stock Exchange
2022-06-17 18:24
Treadwell Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor, CFI-402257, in Patients with ER+/Her2- Breast cancer
2022-06-14 04:01
Centre on Customer Needs CPIC's 31st Anniversary Board of Directors Leads Quality Development
2022-05-13 15:31
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia
2022-04-27 04:30
HUANENG POWER INTERNATIONAL, INC. RMB956 MILLION NET LOSS ATTRIBUTABLE TO EQUITY HOLDERS FOR THE FIRST QUARTER OF 2022 DECREASED BY 129.96%
2022-04-27 00:02
1
2
3
4
5